SCHEDULE 13G/A 0001855655 XXXXXXXX LIVE 1 Common Stock, $0.0001 par value per share 12/31/2025 0001817229 VOR Biopharma Inc. 929033207 500 Boylston Street Suite 1350 Boston MA 02116 Rule 13d-1(c) Paradigm BioCapital Advisors LP b DE 1750000.00 0.00 1750000.00 0.00 1750000.00 N 4.5 PN Paradigm BioCapital Advisors GP LLC b DE 1750000.00 0.00 1750000.00 0.00 1750000.00 N 4.5 OO limited liability company Senai Asefaw, M.D. b X1 1750000.00 0.00 1750000.00 0.00 1750000.00 N 4.5 IN Paradigm BioCapital International Fund Ltd. b E9 1546061.00 0.00 1546061.00 0.00 1546061.00 N 4.0 CO VOR Biopharma Inc. 500 Boylston Street, Suite 1350, Boston, MA 02116 This Schedule 13G is filed by the following (the "Reporting Persons"): (1) Paradigm BioCapital Advisors LP (the "Adviser"); (2) Paradigm BioCapital Advisors GP LLC (the "Adviser GP"); (3) Senai Asefaw, M.D. ("Senai Asefaw"); and (4) Paradigm BioCapital International Fund Ltd. (the "Fund"). The Fund is a private investment vehicle. The Fund and one or more separately managed accounts managed by the Adviser (the "Account") directly beneficially own the Common Stock reported in this statement. The Adviser is the investment manager of the Fund and the Account. The Adviser GP is the general partner of the Adviser. Senai Asefaw is the managing member of the Adviser GP. The Adviser, the Adviser GP and Senai Asefaw may be deemed to beneficially own the Common Stock directly beneficially owned by the Fund and the Account. Each Reporting Person disclaims beneficial ownership with respect to any Common Stock other than the Common Stock directly beneficially owned by such Reporting Person. The principal business office of the Fund is c/o Walkers, 190 Elgin Avenue, George Town, Grand Cayman KY1-9001, Cayman Islands. The principal business office of the Adviser, the Adviser GP and Senai Asefaw is 767 Third Avenue, 17th Floor, New York, NY 10017. For citizenship or place of organization see Item 4 of the cover page of each Reporting Person. Y See Item 9 on the cover page for each Reporting Person, and Item 2, which information is given as of the close of business on December 31, 2025, the Date of Event which requires the filing of this Schedule 13G. See Item 11 on the cover page for each Reporting Person. The percentages of beneficial ownership contained herein are based on 38,720,196 shares of Common Stock outstanding as of December 31, 2025, as obtained by the Reporting Persons from a financial professionals platform. See Item 5 on the cover page for each Reporting Person. See Item 6 on the cover page for each Reporting Person. See Item 7 on the cover page for each Reporting Person. See Item 8 on the cover page for each Reporting Person. N Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Paradigm BioCapital Advisors LP /s/ David K. Kim 02/17/2026 Paradigm BioCapital Advisors GP LLC /s/ David K. Kim 02/17/2026 Senai Asefaw, M.D. /s/ Senai Asefaw, M.D. 02/17/2026 Paradigm BioCapital International Fund Ltd. /s/ David K. Kim 02/17/2026